Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

COMy 2019 | Bringing Dara into the first-line for multiple myeloma

Michael O’Dwyer, MD, PhD, from the National University of Ireland, Galway, Ireland, discusses the advantages of bringing daratumumab into the first-line setting as the CyBorD-Dara combination (cyclophosphamide, bortezomib and dexamethasone with daratumumab) for the treatment of multiple myeloma. Here, Prof. O’ Dwyer highlights how cyclophosphamide can activate macrophages, and therefore enhance antibody-dependent cellular phagocytosis. This interview took place at the Controversies in Multiple Myeloma (COMy) 2019 World Congress in Paris, France.